---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027667"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2026-08-13T20:07:45+00:00"
generated_at: "2026-08-13T20:10:24.535192+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q2 2026 net income $1.8M, revenue up 11.5% to $7.2M

## Summary
- Net income $1.8M ($0.20 diluted EPS) vs $0.5M ($0.06) in Q2 2025; adjusted EBITDA $2.7M vs $1.4M.
- Product sales $7.2M, +11.5% YoY; gross margin fell to 33.9% from 43.7% on lower volumes and quality scrap.
- Received $2M legal settlement from former Re-Tain contract manufacturer, boosting net income.
- Cash rose to $8.9M from $3.8M at year-end; working capital $16.6M, equity $31.4M.
- Plans ~$3.5M freeze-drying capacity (H1 2027) and ~$4.5M liquid processing expansion; aims to triple capacity in 18 months.

## SEC filing metadata
- accession: 0001437749-26-027667
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2026-08-13T20:07:45+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774926027667/0001437749-26-027667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774926027667/iccc20260808_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027667
- JSON: https://secwatch.observer/filing/0001437749-26-027667.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027667.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.